TMPRSS2 and prostate carcinoma: Co-IP of PABPC1 using an anti-ERG antibody in TMPRSS2/ERG-positive VCaP prostate cancer cells demonstrated that endogenous ERG-bound PABPC1 (Fig. 2B).